文献速递脊柱关节炎

司库奇尤单抗150 mg治疗强直性脊柱炎5年长期疗效与安全性:MEASURE 1延长研究

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
PubMed 文献 · RMD Open · 2019-09-03

MEASURE 1延长研究纳入274例强直性脊柱炎患者,评估司库奇尤单抗150 mg治疗5年的疗效与安全性。5年时ASAS20/40应答率分别为78.6%/65.2%,BASDAI50应答率63.4%,疗效持续且安全性良好。56.2%的75 mg组患者需加量至150 mg,加量后疗效改善。

要点

  • 司库奇尤单抗150 mg治疗5年ASAS20/40应答率78.6%/65.2%,BASDAI50应答率63.4%。
  • 84%(230/274)患者完成5年治疗,疗效改善持续至5年。
  • 56.2%的75 mg组患者加量至150 mg后ASAS40等应答改善。

核心结论

  • 司库奇尤单抗150 mg在强直性脊柱炎多个疗效领域提供持续5年的疗效,安全性良好且一致。
  • 超过50%的75 mg组患者需要加量至150 mg,加量后疗效改善。

研究设计与样本

  • MEASURE 1延长研究(NCT01863732),为III期核心试验后的3年延长研究。
  • 核心试验2年后,274例接受皮下司库奇尤单抗150或75 mg(经静脉负荷或初始安慰剂治疗至16/24周)每4周给药的患者进入延长研究。
  • 第156周或之后允许根据治疗医生判断将75 mg加量至150 mg(获批剂量)。
  • 第260周(5年)评估包括ASAS20/40及其他疗效指标,数据以观测值呈现。
  • 安全性评估包括所有接受至少1剂研究治疗的患者。

主要发现

  • 274例进入延长研究的患者中,84%(230/274)完成5年治疗。
  • 5年时司库奇尤单抗150 mg组ASAS20/40应答率分别为78.6%/65.2%,BASDAI50应答率63.4%。
  • 5年时BASDAI总分均值(±SD)为2.6±1.76。
  • 疗效结局改善持续至5年。
  • 82例(56.2%)司库奇尤单抗75 mg组患者在第168周后加量至150 mg,加量后ASAS40、ASAS-PR、ASAS 5/6和BASDAI50应答改善。

关键数值与推荐

  • 5年时ASAS20应答率78.6%,ASAS40应答率65.2%,BASDAI50应答率63.4%。
  • 5年时BASDAI总分均值(±SD)为2.6±1.76。
  • 84%(230/274)患者完成5年治疗。
  • 56.2%(82例)75 mg组患者在第168周后加量至150 mg。

临床怎么用

  • 司库奇尤单抗150 mg可用于强直性脊柱炎长期治疗,5年疗效持续且安全性良好。
  • 75 mg治疗应答不佳时可考虑加量至150 mg,加量后疗效可能改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to report end-of-study results on efficacy and safety of secukinumab 150 mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (NCT01863732)). METHODS: After the 2-year core trial, 274 patients receiving subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) every 4 weeks were invited to enter the 3-year extension study. Dose escalation from 75 to 150 mg (approved dose) was allowed at or after week 156 based on the judgement of the treating physician. Assessments at week 260 (5 years) included Assessment of SpondyloArthritis international Society (ASAS) 20/40 and other efficacy outcomes. Data are presented as observed. Safety assessment included all patients who received ≥1 dose of study treatment. RESULTS: Of the 274 patients who entered the extension study, 84% (230/274) completed 5 years of treatment. ASAS20/40 responses were 78.6/65.2%, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response was 63.4% and mean (±SD) BASDAI total score was 2.6±1.76 with secukinumab 150 mg at 5 years. Improvements in efficacy outcomes were sustained through 5 years. A total of 82 patients on secukinumab 75 mg (56.2%) had their dose escalated to 150 mg after week 168; ASAS40, ASAS-PR, ASAS 5/6 and BASDAI50 responses were improved in patients whose dose was escalated from secukinumab 75 to 150 mg. Secukinumab was well tolerated with a safety profile consistent over the course of the study. CONCLUSIONS: Secukinumab 150 mg provided sustained efficacy across multiple domains of AS with a favourable and consistent safety profile through 5-year treatment. Over 50% of patients required dose escalation from 75 to 150 mg and efficacy improved in these patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019. PMID: 31565244. doi:10.1136/rmdopen-2019-001005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。